亚太首展的美敦力全球首款可充电闭环脊髓神经刺激器Inceptiv，曾被《时代》杂志评为2024年最 具突破性的创新之一。该系统能够感知不同动作下脊髓生物信号的变化并实时自动调整刺激，以帮助慢 性疼痛患者获得更加持续一致的治疗体验。 美敦力5款中国首秀展品包括Affera电生理三维导航及脉冲射频消融系统、高度模拟人体天然瓣膜 功能的Avalus Ultra人工心脏瓣膜、直径仅约1.6毫米的OmniaSecure植入式除颤电极导线等。 本届进博会，赛诺菲聚焦心血管、代谢、呼吸、肿瘤等领域，集中展示多款"同类首创"或"同类最 佳"的创新药物和疫苗，其中，心血管领域创新药物阿夫凯泰片与普乐司兰钠注射液是全球首秀。 阿夫凯泰片作为第二代心肌肌球蛋白抑制剂，是肥厚型心肌病领域潜在"同类最佳"治疗方案，将为 这一导致猝死的"隐藏杀手"开启靶向治疗"精准调节"的新时代；普乐司兰钠注射液是首个作用于创新靶 点APOC3 mRNA的 siRNA类药物，有望打破家族性乳糜微粒血症综合征"无药可控"的困局，带来严重 高甘油三酯血症管理新希望。 中新网上海11月6日电 (记者 姜煜)第八届中国国际进口博览会医疗器械及医药保健展区汇聚了 ...

Core Insights - The 8th China International Import Expo (CIIE) is set to open soon, showcasing innovations and enhancing local consumption and city appeal [1] - The medical exhibition area will feature a drug zone aimed at accelerating the market entry of innovative drugs that have not yet been approved in China [1] Group 1: Medtronic Innovations - Medtronic will showcase five products making their debut in China, focusing on advanced treatments for heart-related diseases, including the Affera electrophysiology system and the CathWorks FFRangio system [2] - The company will also present the Avalus Ultra heart valve and the OmniaSecure lead, designed for right ventricular implantation [2] - A notable product is the Inceptiv spinal cord stimulator, which adapts to the body's signals for chronic pain management [2] Group 2: Abbott and Siemens Medical - Abbott will introduce over ten products, including the Diamondback 360™ system for treating severely calcified coronary lesions [5] - Siemens Medical will have its largest exhibition area to date, showcasing new photon-counting CT devices, with two expected to be produced locally by 2026 [5] Group 3: Varian Medical and Sanofi - Varian Medical will present several new cancer treatment products, including the SmART adaptive radiotherapy solution tailored for Chinese clinical needs [7] - Sanofi will debut two innovative cardiovascular drugs, aiming to address unmet medical needs in their respective fields [8] Group 4: Johnson & Johnson's New Products - Johnson & Johnson will highlight several innovative products in the cardiovascular field, including the CEREGLIDE 71 catheter and the OMNYPULSE monitoring catheter [10] - The company will also showcase three new drugs that have not yet been approved in China, including a dual-specific antibody for EGFR/MET [9]

Group 1: Event Overview - The ninth China International Import Expo (CIIE) has officially launched its exhibition recruitment, with over 40 companies signing contracts, covering an exhibition area of 30,000 square meters [1] - The eighth CIIE has signed contracts for over 330,000 square meters of exhibition space, with 170 companies and 27 institutions recognized as "full attendance" participants [2] - The event will feature participation from 60 overseas exhibition groups from 40 countries and regions, with record-high participation from countries like Canada, Malaysia, New Zealand, Norway, and Peru, reflecting confidence in the Chinese economy [2] Group 2: Exhibitor Highlights - L'Oréal, a long-time exhibitor, will showcase new brands and technologies, marking the largest debut scale in its history, and will celebrate the 20th anniversary of its R&D center in China [6] - New Zealand's Fonterra will globally launch three new product categories, including "A2 Grass-fed Pure Milk," targeting the health-conscious Chinese consumer market [9][10] - Medtronic will present over 100 innovative medical technology products, including six global debuts, emphasizing the transformation of exhibition items into market products [20][24] Group 3: Innovation and New Products - The eighth CIIE will introduce a special area for products from least developed countries and a "cross-border e-commerce selection platform" [2] - Siemens Healthineers will showcase its largest exhibition area to date, featuring groundbreaking medical technologies such as the world's first life-sensing PET/MR system [20] - Abbott will debut its breakthrough cardiovascular technology, the Diamondback 360™ system, which aims to improve treatment reliability for coronary artery blockages [21]